NCT04319367View on ClinicalTrials.gov

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
HIV/AIDS and Infections
Interventions
DRUG

Investigational Medicinal Product

Recombinant human monoclonal antibody (mAb) or placebo

Trial Locations (12)

Unknown

RECRUITING

Aarhus University Hospital, Aarhus

RECRUITING

University Hospitals Sussex NHS Foundation Trust, Brighton

RECRUITING

Western General Hospital, Edinburgh

RECRUITING

Barts Health NHS Trust, London

RECRUITING

Chelsea And Westminster Hospital NHS Foundation Trust, London

RECRUITING

Guy's and St Thomas' NHS Foundation Trust, London

RECRUITING

Mortimer Market CNWL Hospital NHS Foundation Trust, London

RECRUITING

Royal Free London NHS Foundation Trust, London

RECRUITING

St Georges Hospital NHS Foundation Trust, London

RECRUITING

Manchester University NHS Foundation Trust, Manchester

RECRUITING

Oxford University Hospitals, Oxford

W2 1NY

RECRUITING

Imperial College NHS Healthcare Trust, London

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

University of Oxford

OTHER

collaborator

Rockefeller University

OTHER

lead

Imperial College London

OTHER